Malaria, medicines and miles: A novel approach to measuring access to treatment from a household perspective. by Palafox, Benjamin et al.
LSHTM Research Online
Palafox, Benjamin; Goodman, Catherine; Hanson, Kara; (2019) Malaria, medicines and miles: a novel
approach to measuring access to treatment from a household perspective. SSM - Population Health,
7. DOI: https://doi.org/10.1016/j.ssmph.2019.100376
Downloaded from: http://researchonline.lshtm.ac.uk/4652296/
DOI: https://doi.org/10.1016/j.ssmph.2019.100376
Usage Guidelines:
Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
https://researchonline.lshtm.ac.uk
Contents lists available at ScienceDirect
SSM - Population Health
journal homepage: www.elsevier.com/locate/ssmph
Article
Malaria, medicines and miles: A novel approach to measuring access to
treatment from a household perspective
Benjamin Palafox⁎, Catherine Goodman, Kara Hanson
Department of Global Health & Development, London School of Hygiene & Tropical Medicine, 15-17 Tavistock Place, London WC1H 9SH, United Kingdom
A R T I C L E I N F O
Keywords:
Antimalarials
Malaria
Access to healthcare
Private sector
Public sector
Health Equity
Population metrics
A B S T R A C T
Nearly a decade after the adoption of confirmed diagnosis and artemisinin combination therapy (ACT) for the
treatment of uncomplicated falciparum malaria, a large treatment gap persists. We describe a novel approach of
combining data from households and the universe of treatment sources in their vicinities to produce nationally
representative indicators of physical and financial access to malaria care from the household’s perspective in
Benin, Nigeria, Uganda and Zambia. We compare differences in access across urban and rural areas, countries,
and over time.
In 2009, more urban households had a provider stocking ACT within 5 km than rural households. By 2012,
this physical ACT access gap had largely been closed in Uganda, and progress had been made in Benin and
Nigeria; but the gap persisted in Zambia. The private sector helped to fill this gap in rural areas. Improvements in
Nigeria and Uganda were driven largely by increased ACT availability in licensed drug stores, and in Benin by
increased availability in unregulated open-air market stalls. Free or subsidised ACT from public and non-profit
facilities continued to be available to many households by 2012, but much less so in rural areas. Where private
sector expansion increased physical access to ACT, these additional options were on average more expensive.
Also by 2012, the majority of urban households in all four countries had access to a provider nearby offering
malaria diagnostic services; however, this access remained low for rural households in Benin, Nigeria and
Zambia.
The methods developed in this study could improve how access to healthcare is measured in low- and middle-
income country settings, particularly where private for-profit providers are an important source of care, and for
conditions that may be treated by informal providers. The method could also lead to better explanations of the
performance of complex interventions aiming to improve healthcare access.
1. Introduction
In 2016, an estimated 216 million cases of malaria worldwide led to
more than 445,000 deaths, mostly among children in sub-Saharan
Africa (WHO Global Malaria Programme, 2017). Effective management
for uncomplicated cases of Plasmodium falciparum malaria, the species
causing the majority of fatal infections, requires confirmed diagnosis
and, if positive, treatment with artemisinin combination therapy (ACT),
ideally prescribed and dispensed from a qualified provider. However,
access to appropriate diagnosis and treatment is still inadequate, re-
sulting in a large treatment gap where many cases are managed sub-
optimally or even go untreated.
To illustrate, although nearly a decade has passed since the World
Health Organization (WHO) updated its guidelines for treating un-
complicated falciparum malaria to recommend confirmed diagnosis
and ACT, it is estimated that among febrile children in sub-Saharan
Africa for whom care was sought, only 30% received a diagnostic test
either by microscopy or rapid diagnostic test (RDT) in 2014-16 (WHO
Global Malaria Programme, 2017). Moreover, many of those with ma-
laria do not receive ACT. For example, studies in Tanzania found that
among cases positive for malaria by reference blood slide, just over half
(50.2%) received ACT in government facilities and less than a third of
those who sought care from private drug stores (Briggs et al., 2014;
Bruxvoort et al., 2013). Many more were not brought for care or
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received older non-artemisinin therapies (nATs), such as sulphadoxine-
pyrimethamine and chloroquine. Widespread parasite resistance has
rendered nATs less effective in many endemic regions of sub-Saharan
Africa (Okell, Griffin, & Roper, 2017; Takala-Harrison & Laufer, 2015).
Poor coverage of effective treatment persists despite considerable
investment by Ministries of Health and their partners in a range of
strategies to address the issue. These interventions typically aim to
reduce critical access barriers in various ways. For example, efforts
have been made to increase ACT and RDT availability at government
facilities, dispense them free of charge from public sector outlets, train
community health workers and private retailers (i.e. pharmacies and
drug stores) to conduct diagnostic testing and dispense appropriate
treatment, curtail the retailing of non-ACT, and lower private sector
ACT prices through subsidies (Global Fund, 2016; Kabaghe et al., 2016;
Rao, Schellenberg, & Ghani, 2013; Visser et al., 2017). The most notable
of these subsidy programmes was the Affordable Medicines Facil-
ity–malaria (AMFm), which was piloted in several endemic countries,
including Nigeria and Uganda, from 2010–12 (Tougher et al., 2012).
The AMFm was a multi-national subsidy programme for ACTs im-
plemented at a national scale in 7 African countries, funded by the
Global Fund to Fight HIV, TB and Malaria. It aimed to increase the
appropriate use of quality-assured ACTs and decrease the use of other
antimalarials, through a combination of ACT subsidies and supporting
interventions such as recommended retail prices and communications
campaigns. However, despite all these efforts, the size of the treatment
gap indicates that much more still needs to be done to improve malaria
case management.
Within the international public health community, it is now widely
acknowledged that access to health care is a multi-dimensional concept
based on the interaction or ‘degree of fit’ or ‘alignment’ between health
care systems and individual, household, and community needs, which
may either empower or hinder an individual’s use of appropriate health
care (Lévesque, Harris, & Russell, 2013; McIntyre, Thiede, & Birch,
2009). One such definition developed by McIntyre and colleagues ca-
tegorises the many factors that determine access into three dimensions:
availability or physical access, affordability or financial access, and
acceptability or cultural access (McIntyre et al., 2009). In addition, it
has been argued that efforts to understand health care use must account
for the broader range of treatment options that an individual might
engage with, beyond official medical sources (MacKian, Bedri, & Lovel,
2004). This is of particular relevance for malaria treatment, which is
known to involve a diverse array of providers ranging from public,
private and faith-based health care facilities, to retail pharmacies, drug
stores, and general retailers (Littrell et al., 2011).
Efforts to define health care access have tended to focus on its
conceptualisation, without much attention to the application of the
concept or its measurement (McIntyre et al., 2009). Indeed, this is
evident in many of the common indicators used to measure access. For
example, access indicators derived from household data such as De-
mographic and Health Surveys (DHS), Multiple Indicator Cluster Sur-
veys and Malaria Indicator Surveys (ICF International, 2015; Roll Back
Malaria Partnership, 2013; UNICEF, 2015), may provide information on
distance or travel time to the chosen health care provider, the type of
treatment obtained and its price. However, these indicators do not give
information on the broader range of provider options available to that
individual or to individuals not seeking treatment, or on the range and
price of the alternative treatments that providers offer. In particular,
these data do not reveal whether a household has at least one provider
in their area with the required health products and services. In the case
of malaria, such information is critical to understand the choice not to
seek care or to obtain sub-optimal treatment.
On the other hand, health care facility or provider surveys and
administrative datasets may be able to provide comprehensive de-
scriptions of the supply side. For example, the Service Provision
Assessment surveys offered by the DHS collect data on the specific
health services offered by facility type and whether these facilities have
the necessary infrastructure, resources and support systems available
(ICF International, 2015). However, such average data on provider
readiness cannot reveal what a given household’s access to these ser-
vices actually is, especially as the better performing facilities may be
clustered geographically, and such assessments rarely include all pro-
vider types. Such indicators also cannot also account for how well ac-
cessible health care products and services align with actual need.
Therefore, measures of access that combine both household and
provider data to characterise all the treatment options available to an
index household could substantially improve our understanding of
health care access. This paper describes a novel method to develop such
measures by combining supply- and demand-side survey data from the
ACTwatch project to produce nationally representative indicators of
access to care for malaria. We demonstrate the utility of this approach
by estimating a select range of physical and financial access indicators
that characterise the malaria treatment options available to households
with a febrile child in Benin, Nigeria, Uganda and Zambia, and use
these to describe how access has changed over time.
2. Methods
2.1. Data and source
The ACTwatch project was designed to generate nationally re-
presentative information on antimalarial markets through linked cross-
sectional surveys of households, treatment sources and private sector
distribution chains in selected endemic countries (Shewchuk et al.,
2011). Participating countries were chosen to represent a diverse range
of contexts considering variation in malaria burden, the nature of
pharmaceutical regulation (e.g. high vs. low regulatory capacity; fran-
cophone vs. anglophone settings), public sector coverage, and domestic
antimalarial manufacturing capacity.
This study uses household and treatment source data from two
survey rounds conducted in Benin, Nigeria, Uganda and Zambia. We
selected two countries which had received the AMFm antimalarial
subsidy (Nigeria and Uganda) and two which had not (Benin and
Zambia). The first round (baseline) was conducted in 2009-10 (pre-
AMFm), and the second round (endline) in 2011-12 (during AMFm). In
each country and during each round, household and treatment source
surveys were conducted contemporaneously using a common multi-
staged clustered sampling design. Briefly, national samples of house-
holds and treatment sources were drawn from the same primary sam-
pling units (PSUs), within which every treatment source that had re-
cently stocked an antimalarial (i.e. within the preceding three months)
was eligible for inclusion. Treatment sources were identified using a
census approach and included public and not-for-profit health facilities,
private (for-profit) health facilities, retail pharmacies, drug stores
(apart from in Benin; also known as Patent Proprietary Medicine
Vendors, or PPMVs, in Nigeria), and general retailers, such as grocery
stores, kiosks and market stalls (O’Connell et al., 2011). As public
health facilities and pharmacies are important, but relatively un-
common sources of antimalarials, these provider types were over-
sampled by including such providers in the larger administrative area
from which a given PSU was selected. For example, if the PSU was
defined as the sub-district, all public health facilities and pharmacies in
the whole district within which the sub-district was located were
sampled.
Households containing a recently febrile child were randomly se-
lected from three secondary sampling units drawn within each PSU
surveyed. The household surveys collected demand-side information on
the treatment choices made for febrile children, and on personal and
household characteristics, while the treatment source surveys collected
supply-side information on the availability and price of all antimalarials
and all malaria diagnostics, and other provider characteristics related to
staffing, storage conditions, knowledge, etc. Geographic coordinates
were also collected from all surveyed households and treatment
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sources. Table 1 provides details of the household and treatment source
samples in each country (with breakdown by rural/urban strata in
Appendix Tables A and B); sampling and survey procedures are de-
scribed elsewhere (Littrell et al., 2011; O’Connell et al., 2011;
Shewchuk et al., 2011).
2.2. Producing the access dataset and indicators
In each country, we merged household and treatment source data
for each survey round to create the access datasets. For each surveyed
household with a recently febrile child, a treatment choice set was
defined by forming pairwise links between each household and all
treatment sources surveyed that lay within a 5 km radius, reflecting
likely willingness to travel for antimalarial providers, as noted in the
literature (Noor et al., 2006; Noor, Zurovac, Hay, Ochola, & Snow,
2003; Toda et al., 2012). Straight-line distances between households
and paired treatment sources were calculated using the geodist package
in Stata 13 (StataCorp, 2013), and sources located more than 5 km
away were removed from that household’s treatment choice set. A 5 km
radius was chosen to approximate a one-hour walking distance, which
has been used previously to denote reasonable geographic access in
developing country contexts (Skiles, Burgert, Curtis, & Spencer, 2013;
Smith, Solanki, & Kimmie, 1999; Tanser, 2006). Defining treatment
choice sets in this way potentially introduces a measurement bias when
surveyed households are located close to the border of the PSU. This
would result in underestimation of access because treatment options
close to the household, but outside the PSU border, would be excluded
from the choice set. Such bias is less for public health facilities and
pharmacies as these were oversampled from a larger area surrounding
the PSU; however, statistical comparisons between these and other
provider types are not appropriate given the difference in sampling
approaches.
Using the merged household and treatment source data we char-
acterise health care access from the perspective of households. In this
paper, we present the following nationally representative indicators by
urban and rural location, and by survey round, for an access area de-
fined by a 5 km radius around households: % households with access to
any treatment source stocking any antimalarial; % households with
access to any treatment source stocking ACT; % households with access
to ACT by type of treatment source; % households with access to any
treatment source offering malaria diagnostic services; % households
with access to any treatment source staffed by a qualified health pro-
fessional (i.e. medical doctor, nurse, midwife, pharmacist); % house-
holds with access to any treatment source with ACT, offering diagnostic
services and staffed by a qualified health professional; median number
of treatment sources stocking ACT; and median price for ACT, nAT and
oral artemisinin monotherapy (AMT) tablets.
2.3. Statistical analysis
Indicator estimates were adjusted using inverse-probability sam-
pling weights to account for differences in the household probability of
being selected in those countries where samples were stratified.
Standard error estimation accounted for clustering within primary and
secondary sampling units. Thus, estimates are conservative and reduce
the likelihood of incorrectly rejecting the null hypothesis.
Percentage-based estimates are presented with 95% confidence in-
tervals (CI), and differences in percentages over time are tested against
the null hypothesis of no change. Prices for ACT tablets, the most
common dosage form used for treatment, are presented in adult
equivalent treatment doses (AETDs), a standardised unit that allows for
comparison of products with different treatment regimens. Prices were
adjusted to a 2010 base using the World Bank annual consumer price
index values, and converted to US dollars (USD) using the average
weekly exchange rate in 2010 (O’Connell et al., 2011; Tougher et al.,
2012). Price-based indicators are estimated as medians with inter-
quartile range (IQR), and differences over time are examined using the
Wilcoxon rank-sum test. Analyses were conducted in Stata 13 and R
version 3.0.2 (StataCorp, 2013; The R Foundation for Statistical
Computing, 2013).
Table 1
Characteristics of the household and treatment source samples by survey round and country.
Benin Nigeria Uganda Zambia
Survey round 1 2 1 2 1 2 1 2
Survey Date Apr-Jul
2009
Apr-Jul
2011
Aug-Nov
2009
Oct 2011-Jul
2012
Mar-Apr
2009
Nov 2011-May
2012
Apr-Jul
2009
Mar-Sep
2011
Number of strata 1 1 6 2 2 2 2 2
Total clusters 19 19 110 76 38 44 38 38
Total households screened 2312 3275 4616 7863 2063 5067 2218 *
Number of households with a febrile child under 5
years
874 904 2802 1310 1523 1826 1693 1205
Number of households with multiple febrile cases 63 117 469 216 266 403 188 132
Total febrile children under 5 years surveyed 927 1015 3274 1551 1753 2274 1886 1341
Number of cases receiving an antimalarial 378 533 1060 565 899 1177 709 555
Number of cases for whom no initial treatment was
sought
161 31 129 26 78 61 172 109
Number of cases initially treated at home 409 556 1046 732 615 1376 455 317
Number of cases seeking care from multiple
external sources
36 102 302 162 143 309 119 188
Number of outlets screened 1670 2738 5456 7939 5267 16 207 3378 5436
Number of ineligible outlets 609 1348 3246 6372 3989 12 922 2917 4565
Number of outlets surveyed 1061 1390 2196 1562 1278 3227 461 861
Number of outlets stocking ACT 299 588 1168 947 615 2697 240 474
Number of outlets stocking nAT 828 1119 2042 1433 1159 2920 424 742
Number of outlets stocking oral AMT 46 5 1085 551 167 1 26 8
Number of antimalarial tablets inventoried
Number of ACTs 2023 4009 4614 3254 1162 8770 708 1446
Number of nATs 1730 2220 6565 4289 2275 5083 727 1164
Number of oral AMTs 59 5 1623 697 237 1 20 8
* Households not meeting eligibility criteria were not included in the household survey dataset
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3. Results
3.1. Physical access to ACT and other antimalarials
Differences in physical access to ACTs and other antimalarials were
observed across urban and rural areas and over time. In urban areas,
ACTs were accessible to the majority of households. In all four countries
both at baseline and endline, more than 85% of urban households had
access to at least one source of ACTs within a 5 km radius (Fig. 1).
Physical access to ACTs in rural areas was lower than in urban areas;
however, in Benin, Nigeria and Uganda, household access to ACTs in
rural areas improved over time. For example, the percentage of rural
households in Benin with access to at least one source of ACTs within
5 km increased from 51% to 76% (p-value: 0.023) between surveys. In
Uganda, the urban-rural ACT access gap had largely been eliminated by
2012 where over 95% of households in both urban and rural areas had
access to at least one source of ACT within 5 km, whereas in Zambia,
household access did not improve in rural areas between baseline and
endline. In addition, no notable changes in physical access to any an-
timalarial were observed over time in any of the study countries. As
such, the significant improvements in ACT access noted in rural areas of
Benin, Nigeria and Uganda may indicate that over time existing sources
previously stocking only non-ACTs have begun to stock ACT as well.
Our analysis was based on repeated cross-sectional surveys rather
than panel data (i.e. different PSUs were selected in each round). While
each round was designed to be nationally representative, it is possible
that the selection of outliers in terms of PSU characteristics in one
round could have influenced estimates of change over time. Inspection
of sample characteristics disaggregated by urban/rural strata (Appendix
Tables A and B) shows that there were no substantial differences in
average outlet numbers per PSU in all cases except Uganda, where at
endline the urban PSUs selected had a higher average number of anti-
malarial outlets than those selected at baseline (Appendix Tables A and
B). However, this does not affect the patterns described above as the
only notable improvements in access in Uganda were seen in rural
areas.
3.2. Physical access to ACT by treatment source
Examining changes in the composition of treatment sources within
the vicinity of households provides further information on factors
driving the improvements in physical access to ACTs described above
(Fig. 2). During both survey rounds, many urban households had access
to a variety of ACT sources within a 5 km radius, including public and
not-for-profit facilities, private for-profit facilities and retail pharmacies
(Fig. 2a). Nearly all urban households in Nigeria had access to ACTs via
drug stores, which were also common options for households in Uganda
and Zambia. In contrast, households in rural areas had fewer options to
access ACTs (Fig. 2b). Public and not-for-profit health facilities pro-
vided access to ACTs to over half of rural households only in Benin and
Uganda, but were still the most common option in rural Zambia. Drug
stores were the dominant source of ACT accessible to rural households
in Nigeria and for a considerable proportion of households in Uganda.
Over time, there is some evidence that the proportion of urban
households with access to ACTs increased through private for-profit
facilities in Uganda (77% to 96%, p-value: 0.011); drug stores in
Nigeria (89% to 96%, p-value: 0.058); and unlicensed general retailers
in Benin (32% to 83%, p-value: 0.014), Uganda (0% to 16%, p-value:
0.064) and Zambia (0% to 36%, p-value: 0.001). In the four countries,
there were no significant increases in household access to ACTs through
public or not-for-profit providers observed in urban areas; however, in
rural areas of Uganda, the proportion of households with access to ACT
through these providers increased from 56% to 85% (p-value:<
0.001). There is also evidence that rural household access improved
through private health facilities in Uganda (15% to 52%, p-value:<
0.001); drug stores in Nigeria (46% to 70%, p-value: 0.020), Uganda
(24% to 92%, p-value:< 0.001) and Zambia (0% to 12%, p-value:
0.029); and unlicensed general retailers in Benin (11% to 46%, p-value:
0.015) and Nigeria (1% to 8%, p-value: 0.094).
In Table 2, we present figures for the median number of treatment
sources stocking ACT within 5 km of households over time. In Uganda,
the number of ACT providers that a typical household could choose
from increased eightfold between 2009-10 and 2011-12, from a median
Fig. 1. Percentage and 95% confidence interval of households with access to ACT and any antimalarial within 5 km by urban-rural location and over time, with 95%
confidence interval (For differences in percentages over time: * p≤0.1, ** p≤0.05, *** p≤0.001).
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of 10 to 80 providers for urban households, and from a median of 1 to 8
providers for rural households. More modest increases were observed
for rural households in Benin and Nigeria, where the median rose from
1 in 2009-10 to 2 by 2011-12. There were no notable changes in rural
Zambia. These households had access to a median of 0 treatment
sources stocking ACT within 5 km in both survey rounds.
3.3. Physical access to malaria diagnostic services and qualified health
professionals
Urban households had ready access to health professionals and
malaria diagnostic services (Fig. 3a). More than 90% of these house-
holds in all four study countries had at least one antimalarial source
Fig. 2. Percentage and 95% confidence interval of (a) urban and (b) rural households with access to ACT within 5 km by treatment source and over time, with 95%
confidence interval (For differences in percentages over time within sources: * p≤0.1, ** p≤0.05, *** p≤0.001. Notes: Drug stores were not surveyed in Benin as
they are not a common provider type; comparisons across types of treatment source may not be appropriate as public facilities and pharmacies were oversampled in
ACTwatch surveys).
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Table 2
Median number of treatment sources stocking ACTs within 5 km of urban and rural households over time, with interquartile range (IQR).
Urban Rural
Median IQR p-value Median IQR p-value
Benin N Baseline=269, Endline=241 Baseline=595, Endline=659
Baseline 5 (3–28) 0.211 1 (0–3) 0.086
Endline 20 (9–55) 2 (1–4)
Nigeria N Baseline=995, Endline=726 Baseline=1739, Endline=580
Baseline 10 (6–22) 0.439 1 (0–3) 0.010
Endline 13 (7–29) 2 (0–7)
Uganda N Baseline=154, Endline=908 Baseline=1308, Endline=903
Baseline 10 (9–13) <0.001 1 (0–3) < 0.001
Endline 80 (41–154) 8 (5–13)
Zambia N Baseline=848, Endline=471 Baseline=841, Endline=600
Baseline 11 (4–17) 0.334 0 (0–1) 0.596
Endline 7 (2–16) 0 (0–1)
Fig. 3. Percentage and 95% confidence interval of (a) urban and (b) rural households with access to antimalarial providers with malaria diagnostics; health
professionals; and ACT, diagnostics and health professionals within 5 km (For differences in percentages over time within sources: * p≤0.1, ** p≤0.05, ***
p≤0.001. Note: Drug stores were not surveyed in Benin as they are not a common provider type).
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staffed by a qualified health professional within 5 km, and similar
proportions of urban households also had at least one antimalarial
source that offered malaria diagnostic services within 5 km in all
countries except Nigeria. In rural areas, households in Uganda had a
comparable level of access to health professionals as in urban areas, but
access to health professionals was lower in rural areas in the remaining
countries (Fig. 3b). Household access to diagnostic services in rural
areas was poor at just over 50% of households in Benin and over 40% in
Zambia. Rural access to diagnostics in Nigeria increased from 12% to
24% of households between surveys (though this change was not sta-
tistically significant); and increased from 52% to 89% of rural house-
holds in Uganda (p-value:< 0.001).
Fig. 3 also illustrates changes in household access within 5 km to
any treatment sources stocking both ACT and malaria diagnostics, and
staffed by a qualified health professional - the three core elements of
malaria case management. More than half of urban households in all
four countries had access to at least one of these providers in 2009-10
and 2011-12, and more than 90% of urban households in Uganda and
Zambia (Fig. 3a). This access was much lower for rural households
(Fig. 3b). Less than a quarter of rural households in Benin and Nigeria,
and approximately 40% in rural Zambia had access to any treatment
source stocking both ACT and malaria diagnostics, and staffed by a
qualified health professional in 2009-10 and 2011-12. Over time im-
proved access to these providers was observed only in rural Uganda,
where the proportion of households with such access increased from
38% in 2009-10 to 86% by 2011-12 (p<0.001).
3.4. Price of antimalarials accessible to households
Because public and not-for-profit health facilities typically dispense
ACT free of charge or at heavily subsidised prices (as in Benin), low-cost
ACT was accessible to a large majority of urban households in the study
countries with access via these treatment sources (Fig. 2a). In contrast,
fewer rural households had ready access to affordable ACTs via public
and not-for-profit health facilities (Fig. 2b), which could result in de-
layed treatment or seeking care from more expensive private for-profit
providers. Fig. 4 illustrates the median price of ACT (per AETD, 2010
USD) available from private for-profit providers only among those
households with access to them by country, urban-rural location and
over time.
At baseline, the median price of private sector ACT tablets acces-
sible to urban households ranged from 4.94 USD per AETD in Nigeria to
8.33 USD in Zambia, and for rural households from 3.01 USD in Nigeria
to 8.44 USD in Benin. In all countries except Benin, prices for ACT
tended to be higher in urban than in rural areas.
Over time, the median prices of ACT accessible to households de-
creased in all areas of the study countries. However, these changes were
statistically significant for urban and rural households in Nigeria (rural:
from 4.94 to 2.16 USD, p-value:< 0.001; urban: from 3.01 to 1.71 USD,
p-value:< 0.001), rural households in Benin (from 8.44 to 2.55 USD, p-
value:< 0.001), and urban households in Zambia (from 8.33 to 6.75
USD, p-value: 0.001). No significant changes were observed in Uganda.
Median prices for private sector AMT and nAT, and addition details for
ACT tablets are presented in Appendix Table C.
4. Discussion
4.1. Summary of findings and policy implications
By combining data from households with information on the com-
plete range of treatment sources in their vicinities, we have produced a
variety of nationally representative indicators that describe malaria
treatment access from the household perspective, and how this has
changed over time in dynamic, pluralistic health care markets. We
characterise two out of the three dimensions of access (i.e. physical and
financial), but do not address the acceptability dimension.
Our findings show that by 2011-12, although the urban-rural gap in
physical ACT access persisted in Zambia, progress had been made in
Benin and Nigeria, and this gap had largely closed in Uganda. The re-
sults also demonstrate that the private sector helped reduce this gap in
underserved areas. This was seen in Nigeria and Uganda where in-
creased household access was driven largely by increased ACT avail-
ability in licensed drug stores, which was in large part due to these
countries’ participation in the AMFm ACT subsidy programme that
Fig. 4. Median price and interquartile range of private sector ACT tablets (2010 USD) per adult equivalent treatment dose within 5 km of urban and rural households
over time (For differences in median over time: * p≤0.1, ** p≤0.05, *** p≤0.001).
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explicitly aimed to increase ACT availability and affordability among
private retailers (Tougher et al., 2012). Although Benin did not parti-
cipate in AMFm previous research has shown that Benin’s private retail
sector is heavily dependent on Nigeria for antimalarial supplies
(Palafox et al., 2014), so that the impact of AMFm was indirectly felt in
Benin as well. After the official end of AMFm, ACT subsidies were
maintained in Nigeria and Uganda under the Private Sector Co-payment
Mechanism, which sustained the improvements in access achieved
during the AMFm period (ACTwatch Group, Tougher, Hanson, &
Goodman, 2017).
However, increasing physical access through private for-profit
providers carries potential consequences for the affordability of care.
Although we do not measure ability to pay, our data on price are an
important component of financial access. To illustrate, access to ACT
for rural households in Uganda in 2009-10 was predominantly via
public and not-for-profit health facilities where treatment should be
dispensed free of charge. The increases in physical access seen by 2011-
12 were driven largely through more private for-profit health facilities
and drug stores stocking ACT. Although free treatment from public and
not-for-profit facilities was still available to rural households in Uganda
in 2011-12, individuals may choose to purchase more expensive ACT
from private providers because they may be more convenient in terms
of proximity, waiting times and opening hours. However, the observed
decreases in private sector ACT prices demonstrate the role that inter-
ventions, like the AMFm ACT subsidy programme, continue to play in
ensuring wide access to more affordable ACTs (ACTwatch Group,
Tougher, et al., 2017). Nonetheless, improving physical access to af-
fordable care in public facilities must remain as a core objective of
equitable health system strengthening in these settings as even sub-
sidised ACT will still be out of reach for many.
Results from Benin and rural Zambia also illustrate some less de-
sirable effects of broader private sector involvement, where rising ACT
availability among general retailers contributed to the observed in-
crease in household access. In Benin, previous studies have shown that
unlicensed and unregulated open-air market stalls selling antimalarials
dominate this class of provider (O’Connell et al., 2011), among whom it
would be difficult to ensure the quality of medicines and case man-
agement. On the other hand, it could be argued that it is unrealistic to
expect most people to seek care through Benin’s mainly urban private
facilities and pharmacies, and therefore, steps should be taken to in-
crease the quality of alternative treatment sources. Such measures could
include introducing a category of regulated medicine dispenser akin to
drug stores in other countries, support for market stall vendors who
wish to upgrade, and training on malaria case management for drug
store operators (Goodman et al., 2007; Rao et al., 2013).
While our findings show that the ACT access gap is closing, they also
illustrate that, apart from in Uganda, much more could be done to
improve rural access to the other core elements of appropriate malaria
case management - diagnostics and qualified health professionals. By
2011-12, among rural households in Benin, Nigeria and Zambia, less
than 70% had access to a treatment source within 5 km staffed by a
qualified health professional, and less than half had access to malaria
diagnostics. Access to an outlet within 5 km with all three core elements
of malaria case management in rural areas was 40% of households in
Zambia, 27% in Benin and only 16% in Nigeria. Public and private
health facilities continue to be the dominant providers of diagnostic
services in endemic countries (ACTwatch Group, Hanson, & Goodman,
2017). Given the positive impact that engagement with private provi-
ders has had on improving access to ACT, careful consideration needs to
be given to the role private retailers should play in ensuring that ma-
laria diagnostics, and rapid diagnostic tests in particular, cover the last
mile (Visser et al., 2017).
4.2. Methodological insights into measuring health care access
We believe that the methods presented here produce indicators of
access that improve upon those previously used, and that they have
many useful applications. First, we have demonstrated how examining
treatment availability and prices charged from the perspective of
households provides more intuitive and meaningful descriptions of
access. As described in the introduction, typical access indicators are
often limited to demand- or supply-side descriptions, typically averaged
over broad strata (e.g. urban/rural), while our indicators provide direct
measures of the services obtainable within a reasonable distance from
households, thus providing evidence on ‘last mile’ coverage (Lévesque
et al., 2013; McIntyre et al., 2009).
A further advantage of this approach is that access to health services
can be aligned with actual need. To do this for our malaria case study, we
use information from the ACTwatch household survey on reported fever
for a child under the age of 5 years, which other open access resources,
such as maps of populations or structures, do not provide. While re-
ported fever in the study countries was widely distributed, this aspect of
the approach could be more important for other conditions that are
more geographically clustered, such as HIV and tuberculosis.
When such fine-grained descriptions of access are examined over
time, these indicators also provide much clearer understanding of
whether household access has improved, and the changes driving those
improvements. When considered alongside the acceptability dimension
of access, this can indicate how such changes may impact treatment
utilisation and ultimately, health outcomes. In applying these methods
to malaria treatment, we have probed such access changes in Benin,
Nigeria and Uganda, and the lack thereof in Zambia. These indicators
could then be used as explanatory variables in analysing changes in
treatment seeking behaviour. Given this explanatory potential, such
indicators could be used to better evaluate the impact of interventions
designed to improve access to care.
These particular strengths of our method rely not only on the ability
to combine contemporaneous demand- and supply-side data from the
same locations, but also on the comprehensiveness of the supply-side
data. A number of previous analyses have linked Service Provision
Assessment data with DHS household data in novel and interesting
ways (Akin, Guilkey, Hutchinson, & McIntosh, 1998; Skiles et al.,
2013). However, Service Provision Assessments focus on public and
private facilities only and, therefore, do not provide information on the
availability of other treatment options, particularly in the retail sector
which is such an important source of malaria treatment. By contrast,
the ACTwatch treatment source surveys provide a complete picture of
the treatment landscape.
However, conducting simultaneous household and treatment source
surveys is logistically challenging and costly. This is particularly the
case when including all treatment sources as the presence of less qua-
lified providers and retailers is generally not well-documented,
meaning that a detailed census must be conducted. Since the end of the
ACTwatch project, such total market surveys of malaria treatment
sources are not being conducted, so alternative sources of data would
need to be found to produce comprehensive assessments of access to
malaria treatment. One option could be to expand Service Provision
Assessments to include a census of all provider types in PSUs and collect
a broader range of supply-side data in countries where DHS household
surveys include the malaria module. The methods in this paper could
also be applied using data from ACTwatch’s sister project FPwatch,
which involves surveys of all family planning providers alongside
household surveys (PSI, 2018). Conversely, for cases where concurrent,
co-located household data are not available, open source maps of po-
pulations or structures could be used to locate households and then be
merged with supply-side data from sources such as those described
above. However, since these open access resource typically do not in-
clude information on actual household need for care, this approach
would be better suited to measuring access to care for conditions that
are more or less evenly distributed within a population.
Our approach of using a 5 km radius around households to define
their treatment choice sets represents a fairly simplistic use of
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geospatial data, and we recognise that more sophisticated methods,
such as those that estimate road distance and travel time, could be used
to assess physical access (Al-Taiar, Clark, Longenecker, & Whitty, 2010;
Islam & Aktar, 2011). As described in methods, defining treatment
choice sets in this way also risks underestimating access for households
located close to the borders of sampled PSUs, although the effect of this
bias could be minimised by reducing the radius length used. Other
important biases to consider are those typical when using self-reported
data. For example, social desirability bias may have led to under-re-
porting of antimalarial prices and the availability of undesirable
treatments by providers (i.e. oral AMT). While a methodological
strength of the approach is the full census of treatment sources in PSUs,
some providers with the potential to sell antimalarials may have been
missed, leading to underestimates of treatment availability.
5. Conclusion
In this paper, we have described an approach to operationalise the
physical and financial dimensions of access to health care from the
household perspective. Applying these methods to examine access to
malaria treatment in four endemic countries, we have also illustrated
how this novel approach provides a more useful understanding of ac-
cess to care in pluralist and varied health care markets. This approach
also facilitates an understanding of the drivers of changes in access over
time and could lead to better explanations of the performance of
complex interventions aiming to improve healthcare access.
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Appendix
See Table A.
See Table B.
See Table C.
Table A
Characteristics of the urban household and treatment source samples by survey round and country.
Benin Nigeria Uganda Zambia
Survey round 1 2 1 2 1 2 1 2
Number of strata 1 1 6 2 2 2 2 2
Total clusters 6 6 48 39 4 18 19 19
Total households screened 751 1005 1835 4614 191 2883 1267 *
Number of households with a febrile child under 5 years 272 243 1016 730 157 913 849 512
Number of households with multiple febrile cases 31 28 147 112 14 173 73 39
Total febrile children under 5 years surveyed 299 267 1160 852 170 1103 927 553
Number of cases receiving an antimalarial 168 124 413 309 107 523 298 166
Number of cases for whom no initial treatment was sought 13 3 34 11 5 17 91 39
Number of cases initially treated at home 161 183 436 426 165 683 231 134
Number of cases seeking care from multiple external sources 16 31 96 95 17 170 60 70
Number of outlets screened 1058 2336 4167 5706 566 7914 2651 4328
Number of ineligible outlets 305 1191 2348 4635 483 6455 2322 3712
Number of outlets surveyed 753 1145 1809 1068 83 1423 329 607
Number of outlets stocking ACT 177 461 1032 671 35 1287 162 301
Number of outlets stocking nAT 586 942 1687 981 82 1348 301 528
Number of outlets stocking oral AMT 41 4 958 406 26 1 23 8
Number of antimalarial tablets inventoried
Number of ACTs 1478 3645 4378 2445 51 4908 455 969
Number of nATs 1341 1936 5668 3016 223 2545 525 808
Number of oral AMTs 54 4 1479 532 34 1 15 8
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Table C
Median price and IQR (2010 USD) of private sector antimalarial tablets within 5 km of households by antimalarial type and over time.
Urban Rural
Median IQR p-value N Median IQR p-value N
Benin
ACT tablets Baseline 8.14 (6.26–8.32) 0.077 267 8.44 (8.14–9.24) < 0.001 168
Endline 7.53 (3.14–7.58) 191 2.55 (1.77–7.55) 335
AMT tablets Baseline 9.83 (8.57–10.73) 0.010 121 8.29 (8.29–16.52) 0.297 64
Endline 7.26 (7.26–7.26) 16 5.39 (5.39–5.39) 55
nAT tablets Baseline 0.80 (0.39–1.03) 0.217 267 0.45 (0.26–1.45) 0.153 408
Endline 0.90 (0.48–2.48) 201 0.53 (0.48–1.91) 415
Nigeria
ACT tablets Baseline 4.94 (3.50–5.27) < 0.001 892 3.01 (2.64–3.77) < 0.001 737
Endline 2.16 (1.35–2.32) 702 1.71 (1.35–2.16) 415
AMT tablets Baseline 3.61 (3.01–3.61) < 0.001 899 3.31 (2.71–3.77) 0.003 756
Endline 2.43 (2.16–2.59) 689 2.59 (2.37–2.80) 401
nAT tablets Baseline 0.53 (0.38–0.75) 0.006 922 0.45 (0.30–0.64) 0.690 1214
Endline 0.38 (0.32–0.54) 702 0.46 (0.40–0.54) 473
Uganda
ACT tablets Baseline 5.85 (3.86–6.42) 0.055 148 3.86 (0.39–5.42) 0.266 402
Endline 3.10 (2.32–3.87) 907 1.86 (1.55–2.32) 867
AMT tablets Baseline 8.48 (7.71–9.26) < 0.001 148 9.26 (7.71–9.95) 267
Endline 19.35 (19.35–19.35) 62 n/a n/a 0
nAT tablets Baseline 0.72 (0.47–0.72) < 0.001 148 0.47 (0.43–0.60) < 0.001 1074
Endline 1.63 (1.08–2.44) 907 1.99 (0.77–3.25) 872
Zambia
ACT tablets Baseline 8.33 (7.78–9.37) 0.001 636 7.29 (2.60–8.75) 0.385 109
Endline 6.75 (3.91–7.83) 386 3.91 (0.00–5.87) 91
AMT tablets Baseline 5.42 (5.42–6.67) < 0.001 222 n/a n/a 0
Endline 4.89 (4.70–4.89) 109 n/a n/a 0
nAT tablets Baseline 0.52 (0.46–0.62) 0.011 795 0.50 (0.40–0.62) 0.616 264
Endline 0.49 (0.39–0.49) 440 0.49 (0.39–0.59) 243
This analysis is restricted to the price of antimalarial tablets as the most common dosage form used to treat uncomplicated malaria. At baseline, the median price of
ACT faced by households was similar across urban and rural areas in Benin, but tended to be higher in urban areas in Nigeria, Uganda and Zambia. In all countries,
the median price of ACT faced by households at baseline was many times higher than the price of nAT both in urban and rural areas; and when compared to the price
of AMT, ACT tended to be cheaper in Uganda, more expensive in urban areas of Zambia, and comparable both in urban and rural areas of Benin and Nigeria.
Table B
Characteristics of the rural household and treatment source samples by survey round and country.
Benin Nigeria Uganda Zambia
Survey round 1 2 1 2 1 2 1 2
Number of strata 1 1 6 2 2 2 2 2
Total clusters 13 13 82 37 34 26 19 19
Total households screened 1561 2270 2781 3249 1872 2234 953 *
Number of households with a febrile child under 5 years 602 661 1786 580 1336 913 844 693
Number of households with multiple febrile cases 32 89 322 104 252 230 115 93
Total febrile children under 5 years surveyed 628 748 2114 699 1583 1171 959 788
Number of cases receiving an antimalarial 210 409 647 256 792 654 411 389
Number of cases for whom no initial treatment was sought 148 28 95 15 73 44 81 70
Number of cases initially treated at home 248 373 610 306 563 693 224 183
Number of cases seeking care from multiple external sources 20 71 206 67 126 139 59 118
Number of outlets screened 618 454 1289 2233 4701 8293 727 1108
Number of ineligible outlets 307 184 898 1737 3506 6467 595 853
Number of outlets surveyed 311 270 387 494 1195 1804 132 254
Number of outlets stocking ACT 124 137 136 276 580 1410 78 173
Number of outlets stocking nAT 245 199 355 452 1077 1572 123 214
Number of outlets stocking oral AMT 6 1 127 145 141 0 3 0
Number of antimalarial tablets inventoried
Number of ACTs 574 408 236 809 1111 3862 253 477
Number of nATs 409 331 897 1273 2052 2538 202 356
Number of oral AMTs 6 1 144 165 203 0 5 0
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